ANI Pharmaceuticals, Inc. (ANIP)

Environment story

ANI Pharmaceuticals discloses no Scope 1, Scope 2, or Scope 3 emissions data, net-zero targets, or environmental management initiatives in its 10-K filing. The company operates three pharmaceutical manufacturing facilities (Baudette, Minnesota and East Windsor, New Jersey) and previously operated a facility in Oakville, Ontario (closed March 2023, sold March 2024). Risk factors acknowledge climate-change vulnerabilities including extreme weather impacts on facilities and supply chains, and regulatory/governmental responses to climate change that could increase operating costs. No documented controversies regarding toxic waste, water consumption, or habitat damage are disclosed. The absence of any environmental disclosure or commitment statements results in maximum deductions for undisclosed Scope 1/2/3 emissions and missing net-zero targets, partially offset by the absence of documented resource controversies.

Social story

ANI Pharmaceuticals provides minimal disclosure on CEO-to-worker pay ratios, diversity metrics, or labor relations. The 10-K identifies the company's reliance on key employees and management but does not publicly disclose executive compensation ratios, workforce turnover rates, or safety statistics. No active union-suppression activities, documented strikes, or major labor controversies within the past 24 months are disclosed. Diversity statistics for leadership or technical roles are not reported. Supply-chain audits and human-rights hazard mitigation are not documented. The company acknowledges broad healthcare-law compliance obligations and data-protection requirements (HIPAA, GDPR, CCPA) but does not detail labor practices or supply-chain ethics audits. Absence of documented controversies and explicit union disputes is noted, but lack of transparency on pay equity, diversity, and turnover prevents higher scoring.

Governance story

ANI Pharmaceuticals does not disclose board-independence percentages, share-class structure details, or annual lobbying expenditures in its 10-K. The company is subject to broad federal and state healthcare regulations including the Anti-Kickback Statute (AKS), False Claims Act, and Medicaid/Medicare rebate programs; the 10-K extensively documents regulatory compliance risks and potential penalties but does not indicate active regulatory proceedings, SEC consent decrees, or antitrust litigation at filing. No evidence of dual-class voting or unequal shareholder rights is disclosed. No active lobbying targeting environmental deregulation or consumer-protection rollback is disclosed. Risk factors acknowledge the company's significant compliance burden across healthcare laws, data protection (GDPR, CCPA, HIPAA), and FDA manufacturing standards (cGMP), but no consent decrees or major fines are reported. The Loper Light decision is noted as a potential future regulatory uncertainty. Lack of board-independence transparency and missing lobbying disclosures prevent higher scoring.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of ANI Pharmaceuticals, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open ANI Pharmaceuticals, Inc. in the app for interactive charts and portfolio building.

More in Healthcare